Traci advises health care organizations and innovative technology companies, including hospitals, health systems, biotechnology and medical technology (MedTech) companies, digital health companies, and wearable device manufacturers, on federal health care policy, legislative strategy, and executive branch engagement. She brings over two decades of experience across Congress, federal agencies, and the private sector to help organizations navigate regulatory environments, secure federal market access, and advance their health care priorities.
Her work encompasses federal market access, Medicare and Medicaid reimbursement, laboratory policy, the 340B Drug Pricing Program, rural health, telehealth, health information technology and interoperability, aging policy, adoption policy, and organ procurement and transplantation policy, with matters touching the US Department of Health and Human Services, CMS, FDA, HRSA, SAMHSA, NIH, ONC/ASTP, ACL, and ACF.
At HHS, Traci served nearly a decade in senior roles, including Deputy Assistant Secretary for Legislation, overseeing legislative portfolios for multiple agencies. She advised the HHS Secretary on the 340B Drug Pricing Program, organ procurement and transplantation reform, rural health, telehealth, health information technology, and aging and adoption policy, including passage of legislation reauthorizing the Older Americans Act.
Previously, she served as attorney advisor at the HHS Office of Inspector General and as Republican professional staff on the US House Committee on Energy & Commerce, where she co-authored provisions of the landmark 21st Century Cures Act and contributed to the Medicare Access and CHIP Reauthorization Act (MACRA).
She also advised health care and technology clients in private practice and consulting roles on Medicare and Medicaid reimbursement, FDA policy, laboratory policy and physician self-referral (Stark Law) matters, and federal program compliance.
viewpoints
Aging, Reimagined: Precision Medicine Meets Policy
October 26, 2026 | Blog | By Traci L. Vitek, Theresa Carnegie
Explore how Medicare, AI, GLP-1s, dementia policy, and precision medicine are reshaping aging, care delivery, and healthcare investment.
Mental Health Parity Under the Trump Administration: Where DOL Is Headed and What Congress Is Doing About It
October 14, 2026 | Blog | By Traci L. Vitek, Rachel A. Alexander, Theresa Carnegie
Analysis of Trump-era mental health parity enforcement, DOL's narrowed MHPAEA focus, pending litigation, and bipartisan congressional action.
Departments Finalize Transparency in Coverage Rules: What Health Plans and Issuers Need to Know
October 13, 2026 | Blog | By Rachel A. Alexander, Theresa Carnegie, Traci L. Vitek, Grace Callander, Margaret Collopy
On October 5, 2026, the Departments of Health and Human Services (HHS), Labor, and the Treasury (collectively, the Departments) announced changes to the Transparency in Coverage (TIC) final rules, overhauling the 2020 regulatory framework for group health plans and health insurance issuers. The changes aim to standardize the TIC machine-readable files (MRFs) for greater accuracy and accessibility. The rules take effect December 7, 2026, with requirements phased in through July 2028.
A Discussion on What's Shaping the Future of FemTechKey Takeaways on Policy, FDA Oversight, Privacy, and Investment
October 9, 2026 | Webinar | By Traci L. Vitek, Daniel Cody, Benjamin Zegarelli
Explore key FemTech trends shaping the industry, from FDA oversight and privacy laws to policy shifts, investment readiness, and innovation.
340B Rebate Pilot — The Clock Starts NowTen Plans, 18 Drugs, One Deadline
October 7, 2026 | Blog | By Traci L. Vitek, Emmett R. Jamieson, Theresa Carnegie
HRSA’s 340B rebate pilot starts Jan. 1, 2027. Learn the approved plans, litigation risks, and readiness steps for health systems.
Banning Corporate Medicine: The Costs Congress Isn't Pricing In
October 5, 2026 | Blog | By Traci L. Vitek, Deborah Daccord, Daniel Cody
Senators Warren, Wyden, and Merkley, along with Representatives Hoyle, Ocasio-Cortez, and Subramanyam, have introduced the Stop Corporate Takeovers of Physicians Act. The bill would establish the corporate practice of medicine doctrine, rooted in more than a century of law in about half of the states, as a federal baseline. The bill would require that licensed physicians be majority owners and controlers of medical practices and place limitations upon management services organizations. Its rationale is straightforward: a prior Senate bill titled the Break Up Big Medicine Act asserted that more than 75% of U.S. physicians now work for corporate employers and the sponsors want clinical decisions made by doctors rather than shareholders.
The 340B Squeeze: Academic Medical Centers and Large Health Systems Have the Most to Lose
September 28, 2026 | Blog | By Traci L. Vitek, Theresa Carnegie, Brent Henry
Most of the 340B debate centers on rural hospitals and community health centers. The biggest dollars, however, sit with academic medical centers (AMCs) and large health systems, and that is where Washington’s next three moves converge.
FemTech's Real Test: Can Innovation Solve Rural America's Maternal Health Crisis?
September 14, 2026 | Blog | By Traci L. Vitek, Daniel Cody
Can FemTech help solve rural America’s maternal health crisis? Explore innovations, policy barriers, reimbursement, telehealth and access gaps.
The OPO Rule and Your Hospital's Business ModelWhat Transplant and Donor Hospitals Need to Know as CMS Finalizes the Organ Procurement Organization Rule
August 18, 2026 | Article | By Traci L. Vitek
Learn how OPTN modernization, CMS OPO reforms, and new transplant policies will impact donor hospitals, transplant centers, compliance, and planning.
340B Rebates 2.0: HRSA Revives Its Pilot Program — and Sets Up a Collision Course With Congress
August 17, 2026 | Blog | By Traci L. Vitek, Theresa Carnegie
Events & Speaking
Recognition & Awards
Five HHS OIG Exceptional Achievement Awards (2012 – 2017)
